Abstract
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 2018-20 |
| Number of pages | 3 |
| Journal | Pediatric blood & cancer |
| Volume | 62 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2015 |
| Externally published | Yes |
Keywords
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Ataxia Telangiectasia/complications
- Brentuximab Vedotin
- Cyclophosphamide/administration & dosage
- Epstein-Barr Virus Infections/complications
- Herpesvirus 4, Human
- Hodgkin Disease/complications
- Humans
- Immunoconjugates/administration & dosage
- Male
- Prednisone/administration & dosage
- Procarbazine/administration & dosage
- Remission Induction
- Rituximab/administration & dosage
- Vincristine/administration & dosage
- Young Adult
Fingerprint
Dive into the research topics of 'Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver